Fragmin for VTE in cancer patients

The licence for Fragmin (dalteparin sodium) has been extended to include use in patients with solid tumours for the treatment of symptomatic venous thromboembolism (VTE) and the prevention of recurrence.

Fragmin may now be used for up to six months with a recommended dose of 200 international units/kg once daily for the first month and 150 international units/kg daily for the proceeding months. The dose will need to be adjusted in patients with significant renal failure or chemotherapy-induced thrombocytopenia.

View Fragmin drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...